Yervoy Market Report 2026

Yervoy Market Overview

• The Yervoy market growth in the historic period has been driven by approval for melanoma and solid tumors, success of ctla-4 inhibition • Market expansion is supported by expansion of immunotherapy pipelines, growth of combination regimens • Growth Driver: Increasing Incidence of Melanoma Drives Demand for Advanced Treatment Solutions • Market Trend: Innovative Combination Therapies Yervoy And Opdivo Lead The Way In Cancer Treatment Advancements • North America was the largest region in 2025.

What Is Covered Under Yervoy Market?

Yervoy is a prescription medication containing ipilimumab, a monoclonal antibody used in the treatment of certain cancers by enhancing the body's immune system to fight cancer cells. It is a monoclonal antibody that works by blocking the CTLA-4 (cytotoxic T-lymphocyte antigen 4) receptor on T-cells, a protein that normally downregulates the immune response. The main types of yervoy are 40 ml, and 10 ml. The Yervoy 40 mg dose refers to a specific concentration of ipilimumab, a monoclonal antibody used in immunotherapy, administered to patients to activate the immune system by inhibiting CTLA-4, a protein receptor that downregulates immune responses, thereby enhancing the body's ability to target and destroy cancer cells in conditions such as metastatic melanoma and other cancers as per the prescribed treatment regimen. The various indication includes melanoma, non-small cell lung cancer (nsclc), renal cell carcinoma (rcc), and colorectal cancer (crc). These are distributed through various distribution channels such as hospitals, oncology clinics, retail pharmacies, online pharmacies and used by various end users such as adults, geriatric.

What Is The Yervoy Market Growth Forecast?

The yervoy market size is expected to see rapid growth in the next few years. It will grow to $9.93 million in 2030 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to expansion of immunotherapy pipelines, growth of combination regimens, increasing cancer prevalence, rising oncology investments, improved immune profiling. Major trends in the forecast period include growth of immune checkpoint inhibitors, expansion of combination immunotherapy, rising use in advanced oncology, hospital based immuno oncology care, focus on long term cancer survival.

Global Yervoy Market Segmentation

1) By Type: 40 ml, 10 ml 2) By Clinical Indication: Melanoma, Non-Small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma (RCC), Colorectal Cancer (CRC) 3) By Distribution Channel: Hospitals, Oncology Clinics, Retail Pharmacies, Online Pharmacies 4) By End User: Adult, Geriatric

What Is The Driver Of The Yervoy Market?

The increasing incidence of melanoma is expected to propel the growth of the yervoy market going forward. Melanoma refers to a type of skin cancer that develops in the melanocytes, which produce the pigment melanin responsible for skin color. The rising incidence of melanoma is driven by increased sun exposure, lifestyle changes, and UV radiation due to ozone depletion. Improved awareness and diagnostic methods also contribute to more cases being detected. Yervoy, by targeting the CTLA-4 protein to boost the immune system's ability to detect and attack cancer cells, has proven particularly beneficial for melanoma patients, offering improved survival rates and durable responses even in advanced stages of the disease. For instance, in January 2024, according to the American Cancer Society, a US- based non-profit organization dedicated to eliminating cancer, reported that approximately 100,640 new melanoma cases are expected to be diagnosed in the United States in 2024, with 59,170 cases in men and 41,470 cases in women. Additionally, the organization estimates that 8,290 people will die from melanoma in 2024, with 5,430 men and 2,860 women affected. Therefore, increasing incidence of melanoma drives the yervoy industry.

Key Players In The Global Yervoy Market

Major companies operating in the yervoy market are Bristol-Myers Squibb, Merck & Co., Ono Pharmaceutical

Global Yervoy Market Trends and Insights

Major companies operating in the yervoy market are focusing on developing innovative combination therapies, such as a combination of Opdivo (nivolumab) and yervoy (ipilimumab), to enhance treatment efficacy and broaden the range of cancer indications. The combination of Opdivo (nivolumab) and Yervoy (ipilimumab) synergistically boosts the immune response by targeting complementary immune checkpoint pathways, enhancing efficacy in treating various cancers such as melanoma and renal cell carcinoma. For instance, in June 2024, Bristol Myers Squibb, a US-based company that manufactures pharmaceuticals, announced significant results from the CheckMate-9DW trial, which evaluated the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) as a first-line treatment for patients with advanced hepatocellular carcinoma (HCC). The trial demonstrated that this dual immunotherapy regimen significantly improved overall survival (OS) compared to the standard treatments, lenvatinib or sorafenib. The combination of Opdivo and Yervoy showed a statistically significant improvement in overall survival for patients with advanced HCC compared to those treated with either lenvatinib or sorafenib.

What Are Latest Mergers And Acquisitions In The Yervoy Market?

In September 2024, Ono Pharmaceutical, a Japan-based company that manufactures pharmaceuticals, partnered with Bristol-Myers Squibb KK (BMS KK). This partnership aims to expand the use of Opdivo and Yervoy in treating unresectable advanced or recurrent microsatellite instability-high (MSI-H) colorectal cancer. Through this collaboration, Ono aims to enhance its portfolio of immuno-oncology therapies and address unmet medical needs in cancer treatment. Bristol-Myers Squibb is a Japan-based company that offers yervoy.

Regional Insights

North America was the largest region in the yervoy market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Yervoy Market?

The yervoy market consists of sales of ipilimumab and combination therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Yervoy Market Report 2026?

The yervoy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the yervoy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.